Tempus AI Inc
TEM
ISIN null / Valor 135855934
Tempus AI Inc
UMushroom community rating:
About company
Tempus AI Inc., founded in August 2015 by Eric Lefkofsky, is a technology company specializing in the application of artificial intelligence to cancer care. The company aims to harness real-time healthcare data to personalize diagnostics and treatment plans for cancer patients. With the recruitment of its first employee, Ryan Fukushima, Tempus has focused on developing a robust platform that integrates and analyzes vast amounts of clinical and molecular data. This platform is designed to provide actionable insights to healthcare providers, thereby improving patient outcomes through more precise and tailored treatment strategies.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.11.2025):
Tempus AI Inc reported robust financial performance for the third quarter of 2025, demonstrating significant year-over-year growth across key metrics. The company's latest results highlighted strong revenue and gross profit increases, notable improvements in adjusted EBITDA, and strategic operational milestones, reinforcing its leadership in AI-driven precision medicine.
Revenue Growth
For the third quarter of 2025, Tempus AI Inc achieved revenue of $334.2 million, marking an 84.7% increase year-over-year. Genomics revenue surged to $252.9 million with an impressive 117.2% jump, while Oncology and Hereditary testing contributed robustly to overall performance.
Cost Efficiency & Profitability
The company recorded a quarterly gross profit of $209.9 million, reflecting a 98.4% improvement compared to Q3 2024. Despite a net loss of $80.0 million—driven in part by stock compensation and acquisition-related expenses—adjusted EBITDA turned positive at $1.5 million, demonstrating progress in operational efficiency.
Operational Milestones & Guidance
In addition to strong financial numbers, Tempus AI Inc delivered 217,000 clinical tests in the quarter, achieving a 33% volume growth year-over-year. The company also increased its full-year 2025 revenue guidance to approximately $1.265 billion, projecting around 80% growth and anticipating further EBITDA improvements in Q4.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
11355 M
Market cap (USD)
7,196,566
Daily traded volume (Shares)
34.57 / 32.97
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Winston Hu
EQUITIES OF THE SAME SECTOR
